SwanBio’s Preclinical Data

Swanbio’s latest press release has shown preclinical data to support their new gene therapy treatment for AMN. The data has shown that SBT101 is well-tolerated with favorable safety profile in preclinical models

To read the full press release: https://swanbiotx.com/investors-and-media/updated-preclinical-data-support-potential-of-first-aav-based-gene-therapy-as-a-treatment-for-adrenomyeloneuropathy/